To include your compound in the COVID-19 Resource Center, submit it here.

Leaping for Leptin

More than a decade of unimpressive data had dampened enthusiasm for leptin as an obesity therapeutic when Amylin Pharmaceuticals Inc. acquired rights to the protein from Amgen Inc. in 2006. Three years and two trials later, Amylin has data on a combination therapy approach with a leptin analog that gives the company the chance to monetize its investment.

Under a deal announced last week, the biotech will receive $75 million up front from Takeda Pharmaceutical Co. Ltd.

Read the full 761 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers